September 22, 2017 10:18 PM ET

Healthcare Equipment and Supplies

Company Overview of Bactiguard AB

Company Overview

Bactiguard AB provides solutions for reducing device related hospital and care acquired infections. The company offers Bactiguard Infection Protection (BIP) central venous catheters that are used to administer drugs and intravenous solutions, and blood samples, as well as blood pressure monitoring; and BIP endotracheal tubes for use in airway management by oral or nasal intubation of the trachea. It also provides BIP Foley Catheter, a coated latex catheter that is used for drainage and irrigation of the bladder; and BIP Foley Catheter–Silicone, a silicone catheter for drainage and irrigation of the bladder. The company was founded in 2005 and is based in Stockholm, Sweden.

Biblioteksgatan 25

Stockholm,  114 35

Sweden

Founded in 2005

Phone:

46 84 40 58 80

Fax:

46 84 40 58 90

Key Executives for Bactiguard AB

Chairman and Chief Executive Officer
Age: 51
Chief Financial Officer
Age: 50
Chief Operating Officer
Age: 50
Executive Vice President and Sales Manager
Age: 55
Head of External Affairs
Compensation as of Fiscal Year 2017.

Bactiguard AB Key Developments

The Central Drugs Standard Control Organisation Announces the Regulatory Approval for Bactiguard's Central Venous Catheters in India

The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health & Family Welfare, has announced the regulatory approval of Bactiguard's central venous catheters for infection prevention (BIP CVC). Bactiguard has earlier received product approval for its infection preventive urinary catheters (BIP Foley) and sales in India started in 2015. In parallel, a clinical study, involving 1,000 patients in total, at six prestigious hospitals in different regions of the country is being conducted. The regulatory approval for BIP CVC, a class III product with higher safety requirements than for BIP Foley, which is a class IIb product, is unconditional and there are no requirements for post approval clinical trials. Central venous catheters with antimicrobial coatings have gained increasing importance, given the escalating costs associated with hospital acquired infections, particularly in ICUs where patients are critically ill and CVCs are frequently used in their treatment.

Bactiguard Wins Tender for Urinary Catheters for Stockholm County Council

Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary care to purchase Bactiguards' anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years. The contract runs for two years from 6 November, 2017 and comprises BIP Foley Catheter in latex, BIP Foley Catheter Silicone and BIP Foley Tiemann.

Bactiguard AB Reports Earnings Results for the Third Quarter and Nine Months Ended of September 30, 2015

Bactiguard AB reported earnings results for the third quarter and nine months ended of September 30, 2015. For the quarter, the company’s revenues amounted to SEK 61.4 million against of SEK 28.1 million. The increase of 118 % compared to the corresponding quarter 2014 is mainly attributable to the additional order from C.R. Bard. EBITDA amounted to SEK 33.9 million against of SEK 2.2 million. Operating profit amounted to SEK 25.7 million compared to operating loss of SEK 5.3 million. Net profit amounted to SEK 6.1 million compared to net loss of SEK 15.7 million, corresponding to SEK 0.18 and SEK 0.47 per share. Operating cash flow for the quarter amounted to SEK 9.5 million compared to negative operating cash flow of SEK 21.8 million, corresponding to SEK 0.29 or SEK 0.66 per share. For the nine months, the company’s revenues for the period amounted to SEK 118.0 million compared to SEK 93.8 million, an increase by 26 % compared to the corresponding nine-month period last year. The increase is mainly attributable to the additional order from C.R. Bard. Negative EBITDA for the period amounted to SEK 2.9 million compared to EBITDA of SEK 14.2 million. Adjusted for these items, EBITDA amounted to SEK 32.5 million. Operating loss amounted to SEK 27.4 million compared to SEK 8.2 million a year ago. Net loss for the period amounted to SEK 36.4 million compared to SEK0 79.4 million, corresponding to SEK 1.09 and SEK 3.17 per share. Negative operating cash flow amounted to SEK 6.9 million against of SEK 12.4 million, corresponding to SEK 0.21 and SEK 0.5 per share.

Similar Private Companies By Industry

Company Name Region
ABIGO Medical AB Europe
Abilia Sverige Holding AB Europe
Activa Care AB Europe
Aditus Medical AB Europe
Adolesco AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bactiguard AB, please visit www.bactiguard.se. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.